Abstract
Sepsis is a leading cause of morbidity and mortality worldwide. Early identification of sepsis is important as it allows timely administration of potentially life-saving resuscitation and antimicrobial therapy. We present COMPOSER (COnformal Multidimensional Prediction Of SEpsis Risk), a deep learning model for the early prediction of sepsis, specifically designed to reduce false alarms by detecting unfamiliar patients/situations arising from erroneous data, missingness, distributional shift and data drifts. COMPOSER flags these unfamiliar cases as ‘indeterminate’ rather than making spurious predictions. Six patient cohorts (515,720 patients) curated from two healthcare systems in the United States across intensive care units (ICU) and emergency departments (ED) were used to train and externally and temporally validate this model. In a sequential prediction setting, COMPOSER achieved a consistently high area under the curve (AUC) (ICU: 0.925–0.953; ED: 0.938–0.945). Out of over 6 million prediction windows roughly 20% and 8% were identified as ‘indeterminate’ amongst non-septic and septic patients, respectively. COMPOSER provided early warning within a clinically actionable timeframe (ICU: 12.2 [3.2 22.8] and ED: 2.1 [0.8 4.5] hours prior to first antibiotics order) across all six cohorts, thus allowing for identification and prioritization of patients at high risk for sepsis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr. Nemati is funded by the National Institutes of Health (#K01ES025445; #R56 LM013517), Biomedical Advanced Research and Development Authority (#HHSO100201900015C), and the Gordon and Betty Moore Foundation (#GBMF9052). Dr. Wardi is supported by the National Foundation of Emergency Medicine and funding from the Gordon and Betty Moore Foundation (#GBMF9052). He has received speaker's fees from Thermo-Fisher and consulting fees from General Electric. Dr. Malhotra is funded by NIH. He reports income related to medical education from Merck and Livanova, and a philanthropic donation from ResMed to UC San Diego. Dr. Shashikumar has no conflicts of interest and sources of funding to declare. The opinions or assertions contained herein are the private ones of the author and are not to be construed as official or reflecting the views of the Department of Defense, the NIH or any other agency of the US Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This investigation was conducted according to University of California San Diego IRB approved protocol #191098 and Emory University IRB Protocol #00110675.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
De-identified data from the Emory cohort has been made available as part of the PhysioNet Challenge 2019. Access to de-identified UCSD cohort may be made available via approval from UCSD Institutional Review Board (IRB) and Health Data Oversight Committee (HDOC). Access to the computer code used in this research is available upon request to the corresponding author.
